,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1195,1,2,,48415923,3157,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
1,1332,1,1,,49698667,3157,Inactive,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
2,2062,1,2,,85209457,3157,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
3,2240,1,1,,85787347,3157,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
4,2241,1,1,,85787347,3157,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
5,2275,1,1,,85787347,3157,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
6,2313,1,1,,85787347,3157,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
7,2316,1,1,,85787347,3157,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Activators of the Reversal of PD-1 Mediated Inhibitors of T-Cell Inhibition,Screening,,
8,2322,1,1,,85787347,3157,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
9,2330,1,1,,85787347,3157,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
10,2660,1,1,,90341261,3157,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
11,2666,1,1,,90341261,3157,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
12,2667,1,1,,90341261,3157,Inconclusive,4826730.0,2475.0,26.1216,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
13,2668,1,1,,90341261,3157,Active,4826730.0,2475.0,11.6681,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
14,27167,3,4,,103194429,3157,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
15,28681,3,4,,103194429,3157,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
16,29123,5,2,,103194429,3157,Active,,,0.0257,Kd,Antagonist dissociation constant in dog prostrate,Confirmatory,10780916.0,
17,29125,5,3,,103194429,3157,Active,,,0.000309,Kd,Antagonist dissociation constant in rat spleen,Confirmatory,10780916.0,
18,29127,5,2,,103194429,3157,Active,,,0.0020399999999999997,Kd,Antagonist dissociation constant in rat vas deferens,Confirmatory,10780916.0,
19,29359,3,3,,103194429,3157,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
20,29813,3,3,,103194429,3157,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
21,35155,6,6,,103194429,3157,Active,543734.0,24173.0,0.000309,Kd,In vitro antagonistic activity against alpha-1B receptor in rat spleen.,Confirmatory,11384242.0,
22,35266,7,2,,103194429,3157,Active,,,0.0011,Ki,Compound was tested for its binding affinity for alpha-1 adrenergic receptor site by displacement of [3H]clonidine at 10e-6 M concentration,Confirmatory,2879919.0,
23,35328,8,5,,103194429,3157,Active,1168243.0,146.0,0.0012,Ki,"Binding affinity against Alpha-1D adrenergic receptor, from human clones.",Confirmatory,7658428.0,
24,35468,5,1,,103194429,3157,Active,,,0.00398,Ki,Binding affinity was tested on human Alpha-1D adrenergic receptor,Confirmatory,9135028.0,
25,35952,8,5,,103194429,3157,Active,1351829.0,150.0,0.7290000000000001,Ki,"Binding affinity against Alpha-2A adrenergic receptor, from human clones.",Confirmatory,7658428.0,
26,36124,8,3,,103194429,3157,Active,,,0.0063100000000000005,Kd,pA2 for Alpha-1 adrenergic receptor from human prostate.,Confirmatory,9135028.0,
27,36231,8,5,,103194429,3157,Unspecified,613504690.0,151.0,5.0,Ki,Binding affinity against Alpha-2B adrenergic receptor from human clones.,Confirmatory,7658428.0,
28,36259,4,6,,103194429,3157,Active,,,,,Antagonist activity against post junctional alpha-1 adrenergic receptor was measured by Kerbs super fused rabbit pulmonary artery preparations labeled with [3H]- norepinephrine.,Other,2879919.0,
29,36408,8,5,,103194429,3157,Active,20141211.0,152.0,0.28,Ki,Binding affinity against Alpha-2C adrenergic receptor from human clones.,Confirmatory,7658428.0,
30,36469,5,4,,103194429,3157,Active,,,0.0257,Kd,In vitro antagonistic activity against alpha-1A receptor in dog prostate.,Confirmatory,11384242.0,
31,36505,3,7,,103194429,3157,Unspecified,,,,,Antagonist activity against prejunctional alpha alpha-2 adrenergic receptor was measured by Kerbs super fused rabbit pulmonary artery preparations labeled with [3H]- norepinephrine.,Other,2879919.0,
32,36506,5,4,,103194429,3157,Inactive,,,,,Antagonist activity against prejunctional alpha-2 adrenergic receptor was measured by Kerbs super fused rabbit pulmonary artery preparations labeled with [3H]- norepinephrine; NA means no activity,Other,2879919.0,
33,36509,6,4,,103194429,3157,Inactive,,,,,Antagonist activity against prejunctional alpha-2 adrenergic receptor was measured by Kerbs super fused rabbit pulmonary artery preparations labeled with [3H]- norepinephrine; NA means no activity,Other,2879919.0,
34,36618,8,5,,103194429,3157,Active,1168246.0,148.0,0.0026,Ki,Binding affinity against Alpha-1A adrenergic receptor from human clone,Confirmatory,7658428.0,
35,36753,5,1,,103194429,3157,Active,,,0.00316,Ki,Binding affinity was tested on human Alpha-1A adrenergic receptor,Confirmatory,9135028.0,
36,37033,6,6,,103194429,3157,Active,1168247.0,29412.0,0.0020399999999999997,Kd,In vitro antagonistic activity towards alpha-1A adrenergic receptor in rat vas deferens,Confirmatory,11384242.0,
37,37252,8,4,,103194429,3157,Inactive,,,,,Tested for its binding affinity for alpha-2 adrenergic receptor site by displacement of [3H]clonidine at 10e-6 M concentration; NA means no activity,Other,2879919.0,
38,37335,8,5,,103194429,3157,Active,116241241.0,147.0,0.00074,Ki,Binding affinity against Alpha-1B adrenergic receptor from human clone,Confirmatory,7658428.0,
39,37478,5,1,,103194429,3157,Active,,,0.001,Ki,Binding affinity was tested on human Alpha-1B adrenergic receptor,Confirmatory,9135028.0,
40,62832,5,2,,103194429,3157,Active,,,0.07586,Kd,In vivo antagonist dissociation constant in intaraurethral pressure model in dogs.,Confirmatory,11384242.0,
41,62833,5,2,,103194429,3157,Active,,,0.07586,Kd,Intraurethral pressure (IUP) in Beagle dogs values are expressed as pseudo pA2 values.,Confirmatory,10780916.0,
42,195503,4,4,,103194429,3157,Unspecified,,,,,Percent reduction in blood pressure in spontaneously hypertensive rats (SHR) at peroral dose of 5 mg/kg was determined after 1 hr,Other,2879919.0,
43,195504,4,4,,103194429,3157,Unspecified,,,,,Percent reduction in blood pressure in spontaneously hypertensive rats (SHR) at peroral dose of 5 mg/kg was determined after 6 hr,Other,2879919.0,
44,197367,3,3,,103194429,3157,Unspecified,,,,,Antagonistic activity in spontaneously hypertensive rat model.,Other,11384242.0,
45,197369,3,3,,103194429,3157,Unspecified,,,,,Determination Pseudo pED50 in Spontaneously Hypertensive Rat (SHR) model,Other,10780916.0,
46,232245,3,3,,103194429,3157,Unspecified,,,,,Selectivity ratio (antolog[pA2 of IUP-pED50 of SHR]) of the compound,Other,11384242.0,
47,232246,3,4,,103194429,3157,Unspecified,,,,,Selectivity ratio (antolog[pA2rat vas deferens/pA2 rat spleen]) of the compound,Other,11384242.0,
48,239799,3,6,,103194429,3157,Unspecified,,,,,Binding affinity for alpha 1a adrenoceptor,Other,16033273.0,
49,239800,3,5,,103194429,3157,Unspecified,,,,,Binding affinity for alpha 1b adrenoceptor,Other,16033273.0,
50,239801,3,5,,103194429,3157,Unspecified,,,,,Binding affinity for alpha 1d adrenoceptor,Other,16033273.0,
51,247991,6,2,,103194429,3157,Active,,,45.0,IC50,Inhibition of prostate cancer (PC-3) cell proliferation,Confirmatory,15317457.0,
52,257357,4,1,,103194429,3157,Active,1168246.0,148.0,0.000537,Ki,Displacement of [3H]prazosin from cloned human ADRA1A expressed in CHO cells,Confirmatory,16302814.0,
53,257358,4,1,,103194429,3157,Active,116241241.0,147.0,0.000813,Ki,Displacement of [3H]prazosin from cloned human ADRA1B expressed in CHO cells,Confirmatory,16302814.0,
54,257359,4,1,,103194429,3157,Active,1168243.0,146.0,0.000813,Ki,Displacement of [3H]prazosin from cloned human ADRA1D expressed in CHO cells,Confirmatory,16302814.0,
55,257360,4,1,,103194429,3157,Inconclusive,231454.0,3350.0,,Ki,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from cloned human 5HT1A receptor expressed in HeLa cells,Confirmatory,16302814.0,
56,257361,3,9,,103194429,3157,Unspecified,1168247.0,29412.0,,,ADRA1A blocking activity assessed by antagonism of (-)-NE induced contractions on isolated rat prostatic vas deferens,Other,16302814.0,
57,257362,3,9,,103194429,3157,Unspecified,543734.0,24173.0,,,ADRA1B blocking activity assessed by antagonism of (-)-phenylephrine induced contractions on isolated rat spleen,Other,16302814.0,
58,257363,3,9,,103194429,3157,Unspecified,1168244.0,29413.0,,,ADRA1D blocking activity assessed by antagonism of (-)-NE induced contractions on isolated rat thoracic aorta,Other,16302814.0,
59,257364,3,10,,103194429,3157,Inconclusive,231454.0,3350.0,,,Agonist efficacy towards cloned human 5HT1A receptor by [35SGTP]gammaS binding in HeLa cells,Other,16302814.0,
60,257365,4,10,,103194429,3157,Inconclusive,231454.0,3350.0,,,Maximum response towards cloned human 5HT1A receptor,Other,16302814.0,
61,257366,7,2,,103194429,3157,Active,,,26.9,GI50,Cytotoxic activity on human PC3 prostate cancer cells by SRB assay,Confirmatory,16302814.0,
62,257369,3,5,,103194429,3157,Inactive,,,,,Inhibition of NE-induced increase of PC3 cell proliferation using ELISA BrdU,Other,16302814.0,
63,294856,3,3,,103194429,3157,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,17336075.0,
64,311524,4,3,,103194429,3157,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
65,386623,4,8,,103194429,3157,Unspecified,313104181.0,6580.0,,,Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy,Other,18788725.0,
66,391760,7,2,,103194429,3157,Active,,,26.9,GI50,Cytotoxicity against human PC3 cells after 48 hrs by SRB assay,Confirmatory,18817363.0,
67,422824,8,5,,103194429,3157,Active,1168246.0,148.0,0.000537,Ki,Displacement of [3H]prazosin from human alpha1A adrenoceptor expressed in CHO cells,Confirmatory,19719240.0,
68,422825,8,5,,103194429,3157,Active,116241241.0,147.0,0.000813,Ki,Displacement of [3H]prazosin from human Alpha-1B adrenoceptor expressed in CHO cells,Confirmatory,19719240.0,
69,422826,8,5,,103194429,3157,Active,1168243.0,146.0,0.000813,Ki,Displacement of [3H]prazosin from human Alpha-1D adrenoceptor expressed in CHO cells,Confirmatory,19719240.0,
70,422827,6,6,,103194429,3157,Active,1168247.0,29412.0,0.0020399999999999997,Kd,Antagonist activity at rat alpha1A adrenoceptor assessed as inhibition if norepinephrine-induced contraction of vas deference,Confirmatory,19719240.0,
71,422828,6,6,,103194429,3157,Active,543734.0,24173.0,0.000309,Kd,Antagonist activity at rat Alpha-1B adrenoceptor assessed as inhibition if phenylephrine-induced contraction of spleen,Confirmatory,19719240.0,
72,422829,6,6,,103194429,3157,Active,1168244.0,29413.0,0.00107,Kd,Antagonist activity at rat Alpha-1D adrenoceptor assessed as inhibition if norepenephrine-induced contraction of thoracic aorta,Confirmatory,19719240.0,
73,422830,6,2,,103194429,3157,Active,,,38.6,IC50,Cytotoxicity against human PC3 cells after 72 hrs by CellTitter-Glo luminescent cell viability assay,Confirmatory,19719240.0,
74,422831,6,2,,103194429,3157,Active,,,37.44,IC50,Cytotoxicity against human DU145 cells after 72 hrs by CellTitter-Glo luminescent cell viability assay,Confirmatory,19719240.0,
75,422832,6,2,,103194429,3157,Active,,,28.11,IC50,Cytotoxicity against human LNCAP cells after 72 hrs by CellTitter-Glo luminescent cell viability assay,Confirmatory,19719240.0,
76,422833,6,2,,103194429,3157,Active,,,43.0,IC50,Cytotoxicity against human NHDF cells after 72 hrs by CellTitter-Glo luminescent cell viability assay,Confirmatory,19719240.0,
77,422834,6,2,,103194429,3157,Unspecified,,,100.0,EC50,Induction of apoptosis in human PC3 cells assessed as caspase 3/7 activation after 24 hrs by Caspase-Glo 3/7 assay,Confirmatory,19719240.0,
78,422835,8,1,,103194429,3157,Unspecified,,,100.0,EC50,Induction of apoptosis in human DU145 cells assessed as caspase 3/7 activation after 24 hrs Caspase-Glo 3/7 assay,Confirmatory,19719240.0,
79,422836,8,1,,103194429,3157,Unspecified,,,100.0,EC50,Induction of apoptosis in human LNCAP cells assessed as caspase 3/7 activation after 24 hrs Caspase-Glo 3/7 assay,Confirmatory,19719240.0,
80,422837,6,2,,103194429,3157,Unspecified,,,100.0,EC50,Induction of apoptosis in human NHDF cells assessed as caspase 3/7 activation after 24 hrs Caspase-Glo 3/7 assay,Confirmatory,19719240.0,
81,422839,3,4,,103194429,3157,Inactive,,,,,"Antitumor activity against human PC3 cells xenografted in NU/NU mouse at 3 mg/kg, po after 21 days relative to control",Other,19719240.0,
82,422840,3,4,,103194429,3157,Inactive,,,,,"Antitumor activity against human PC3 cells xenografted in NU/NU mouse at 10 mg/kg, po after 21 days relative to control",Other,19719240.0,
83,422842,3,4,,103194429,3157,Active,,,,,Induction of apoptosis in human PC3 cells xenografted in NU/NU mouse assessed as DNA fragmentation at 0.3 to 3 mg/kg by agarose gel electrophoresis,Other,19719240.0,
84,422843,3,4,,103194429,3157,Active,,,,,Antiangiogenic activity in human PC3 cells xenografted in NU/NU mouse assessed as reduction vascularization at 3 mg/kg by immunohistochemistry,Other,19719240.0,
85,434959,1,1,,85787347,3157,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
86,463106,1,2,,90341261,3157,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
87,485295,1,2,,90341261,3157,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
88,485297,1,1,,90341261,3157,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
89,485298,1,1,,90341261,3157,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
90,485313,1,2,,90341261,3157,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
91,485342,1,2,,90341261,3157,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
92,485345,1,2,,90341261,3157,Inconclusive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
93,485366,1,2,,90341261,3157,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
94,485368,1,2,,90341261,3157,Inactive,72386991.0,3656265.0,,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
95,485395,1,2,,92241035,3157,Inactive,150392496.0,,,,A screen for compounds that inhibit the activity of Staphylococcus aureus DNA helicase,Other,,
96,488772,1,1,,90341261,3157,Inactive,8659577.0,58819.0,18.8876,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
97,488773,1,2,,90341261,3157,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
98,488816,1,1,,90341261,3157,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
99,488837,1,1,,90341261,3157,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
100,488949,1,2,,90341261,3157,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
101,488953,1,1,,90341261,3157,Inconclusive,187960037.0,10951.0,89.1251,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
102,488978,1,1,,90341261,3157,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
103,488981,1,1,,90341261,3157,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
104,488982,1,1,,90341261,3157,Inactive,4503383.0,1812.0,5.8045,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
105,488983,1,1,,90341261,3157,Inconclusive,4503383.0,1812.0,15.8489,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
106,492967,1,2,,92241035,3157,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
107,493106,1,1,,90341261,3157,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
108,493107,1,1,,90341261,3157,Active,116283940.0,79915.0,23.0999,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
109,493153,1,1,,90341261,3157,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
110,493153,1,1,,90341261,3157,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
111,493164,1,2,,90341261,3157,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
112,493164,1,2,,90341261,3157,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
113,493164,1,2,,90341261,3157,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
114,504327,1,1,,90341261,3157,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
115,504332,1,1,,90341261,3157,Inconclusive,168985070.0,,26.6795,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
116,504536,1,1,,90341261,3157,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
117,504547,1,1,,90341261,3157,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
118,504548,1,2,,90341261,3157,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
119,504770,1,2,,92241035,3157,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
120,504810,1,2,,90341261,3157,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
121,504812,1,2,,90341261,3157,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
122,504836,1,2,,90341261,3157,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
123,504845,1,1,,90341261,3157,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
124,504847,1,1,,90341261,3157,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
125,504865,1,1,,90341261,3157,Inconclusive,118600387.0,7398.0,11.2202,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
126,540209,4,3,,103194429,3157,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
127,540210,4,3,,103194429,3157,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
128,540211,2,5,,103194429,3157,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
129,540212,4,3,,103194429,3157,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
130,540213,4,3,,103194429,3157,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
131,540256,1,2,,90341261,3157,Inconclusive,,,29.081,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
132,540276,1,2,,50105246,3157,Inconclusive,420597.0,,29.0929,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
133,540276,1,2,,90341261,3157,Active,420597.0,,11.5774,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
134,547621,4,3,,103194429,3157,Active,,,27.0,EC50,Cytotoxicity against BESM cells after 88 hrs by HTS assay,Confirmatory,20547819.0,
135,547622,4,2,,103194429,3157,Active,,,12.0,EC50,Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay,Confirmatory,20547819.0,
136,547804,1,3,,103194429,3157,Unspecified,,,,,"Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells",Other,20547819.0,
137,576612,7,5,,103194429,3157,Active,7531135.0,3757.0,0.5888399999999999,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
138,588214,2,3,,103194429,3157,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
139,588215,2,3,,103194429,3157,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
140,588216,2,3,,103194429,3157,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
141,588217,2,3,,103194429,3157,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
142,588218,2,3,,103194429,3157,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
143,588219,2,3,,103194429,3157,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
144,588346,1,1,,124883384,3157,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a: Hit Confirmation in b-rIgG Counterscreen,Confirmatory,,
145,588349,1,1,,90341261,3157,Inconclusive,,,14.1254,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
146,588378,1,1,,90341261,3157,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
147,588453,1,1,,90341261,3157,Inactive,8659577.0,58819.0,19.9526,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
148,588453,1,1,,124883384,3157,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
149,588456,1,1,,90341261,3157,Inactive,8659577.0,58819.0,28.1838,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
150,588456,1,1,,124883384,3157,Inactive,8659577.0,58819.0,50.1187,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
151,588579,1,1,,90341261,3157,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
152,588579,1,1,,124883384,3157,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
153,588590,1,1,,124883384,3157,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
154,588795,1,1,,90341261,3157,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
155,588795,1,1,,124883384,3157,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
156,602332,1,1,,90341261,3157,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
157,624101,1,2,,85787347,3157,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
158,624136,1,1,,85787347,3157,Inactive,208342286.0,7157.0,,,mutant P53 Measured in Biochemical System Using Small Molecule MicroArray - 2077-01_Other_SinglePoint_HTS_Activity,Screening,,
159,624137,1,1,,85787347,3157,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
160,624138,1,1,,85787347,3157,Inactive,21618340.0,6774.0,,,SMM STAT-3 Measured in Biochemical System Using Small Molecule MicroArray - 2076-01_Other_SinglePoint_HTS_Activity_Set2,Screening,,
161,624139,1,1,,85787347,3157,Inactive,34577122.0,4790.0,,,NF-KappaB Measured in Biochemical System Using Small Molecule MicroArray - 2080-01_Other_SinglePoint_HTS_Activity,Screening,,
162,624141,1,1,,85787347,3157,Inactive,71774083.0,4609.0,,,SMM c-myc Measured in Biochemical System Using Small Molecule MicroArray - 2081-01_Other_SinglePoint_HTS_Activity,Screening,,
163,624146,1,1,,90341261,3157,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
164,624147,1,1,,90341261,3157,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
165,624148,1,2,,90341261,3157,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
166,624149,1,1,,90341261,3157,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
167,624151,1,1,,85787347,3157,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Re-Activators of the P53 Mutant Pathway Measured in Cell-Based System Using Plate Reader - 2071-01_Activator_SinglePoint_HTS_Activity,Screening,,
168,624156,1,1,,85787347,3157,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
169,624178,1,1,,124883384,3157,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
170,624202,1,1,,124883384,3157,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
171,624260,1,1,,85787347,3157,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
172,624263,1,1,,124883384,3157,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
173,624263,1,1,,124883384,3157,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
174,624349,1,2,,92309056,3157,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
175,624349,1,2,,121362602,3157,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
176,624414,1,1,,124883384,3157,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
177,624455,1,1,,90341261,3157,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
178,625144,5,5,,103194429,3157,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
179,625145,4,7,,103194429,3157,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
180,625146,5,5,,103194429,3157,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
181,625147,4,7,,103194429,3157,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
182,625148,4,7,,103194429,3157,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
183,625149,4,7,,103194429,3157,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
184,625150,5,5,,103194429,3157,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
185,625151,4,7,,103194429,3157,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
186,625152,4,7,,103194429,3157,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
187,625153,4,7,,103194429,3157,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
188,625154,4,7,,103194429,3157,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
189,625155,4,7,,103194429,3157,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
190,625156,1,9,,103194429,3157,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
191,625157,6,2,,103194429,3157,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
192,625158,3,4,,103194429,3157,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
193,625159,5,5,,103194429,3157,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
194,625160,1,9,,103194429,3157,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
195,625161,4,7,,103194429,3157,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
196,625162,4,7,,103194429,3157,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
197,625163,4,7,,103194429,3157,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
198,625164,1,6,,103194429,3157,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
199,625165,3,4,,103194429,3157,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
200,625166,3,4,,103194429,3157,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
201,625167,5,5,,103194429,3157,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
202,625168,4,7,,103194429,3157,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
203,625169,1,6,,103194429,3157,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
204,625170,3,4,,103194429,3157,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
205,625171,4,7,,103194429,3157,Active,7531135.0,3757.0,2.2155,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
206,625172,4,7,,103194429,3157,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
207,625173,5,5,,103194429,3157,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
208,625174,5,5,,103194429,3157,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
209,625175,5,5,,103194429,3157,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
210,625176,1,9,,103194429,3157,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
211,625177,5,5,,103194429,3157,Active,116852.0,4312.0,5.749,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
212,625178,5,5,,103194429,3157,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
213,625179,1,9,,103194429,3157,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
214,625180,5,5,,103194429,3157,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
215,625181,5,5,,103194429,3157,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
216,625182,5,5,,103194429,3157,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
217,625183,5,5,,103194429,3157,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
218,625184,5,5,,103194429,3157,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
219,625185,5,5,,103194429,3157,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
220,625186,5,5,,103194429,3157,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
221,625187,5,5,,103194429,3157,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
222,625188,1,9,,103194429,3157,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
223,625189,1,7,,103194429,3157,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
224,625190,4,5,,103194429,3157,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
225,625191,4,7,,103194429,3157,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
226,625192,4,7,,103194429,3157,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
227,625193,5,5,,103194429,3157,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
228,625194,4,7,,103194429,3157,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
229,625195,4,7,,103194429,3157,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
230,625196,5,6,,103194429,3157,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
231,625197,3,4,,103194429,3157,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
232,625198,4,7,,103194429,3157,Active,1168247.0,29412.0,0.00155,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
233,625199,4,7,,103194429,3157,Active,543734.0,24173.0,0.0007509999999999999,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
234,625200,4,7,,103194429,3157,Active,1168243.0,146.0,0.0033799999999999998,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
235,625201,4,7,,103194429,3157,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
236,625202,4,7,,103194429,3157,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
237,625203,4,7,,103194429,3157,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
238,625204,4,7,,103194429,3157,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
239,625205,4,7,,103194429,3157,Active,296439450.0,154.0,2.748,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
240,625206,4,7,,103194429,3157,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
241,625207,4,7,,103194429,3157,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
242,625208,5,5,,103194429,3157,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
243,625209,4,7,,103194429,3157,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
244,625210,3,4,,103194429,3157,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
245,625211,1,6,,103194429,3157,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
246,625212,3,4,,103194429,3157,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
247,625213,4,7,,103194429,3157,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
248,625214,1,9,,103194429,3157,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
249,625215,3,4,,103194429,3157,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
250,625216,3,4,,103194429,3157,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
251,625217,4,7,,103194429,3157,Active,1168220.0,3357.0,0.368,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
252,625218,4,7,,103194429,3157,Active,112816.0,3358.0,0.544,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
253,625219,3,4,,103194429,3157,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
254,625220,4,7,,103194429,3157,Active,6224984.0,100135548.0,0.764,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
255,625221,4,7,,103194429,3157,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
256,625222,4,7,,103194429,3157,Active,400630.0,6532.0,2.688,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
257,625223,4,7,,103194429,3157,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
258,625224,3,4,,103194429,3157,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
259,625225,3,4,,103194429,3157,Active,,,1.1,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
260,625226,4,7,,103194429,3157,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
261,625227,4,7,,103194429,3157,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
262,625228,4,7,,103194429,3157,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
263,625229,5,5,,103194429,3157,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
264,625230,1,6,,103194429,3157,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
265,625231,4,7,,103194429,3157,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
266,625232,1,9,,103194429,3157,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
267,625233,4,7,,103194429,3157,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
268,625234,3,4,,103194429,3157,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
269,625235,4,7,,103194429,3157,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
270,625236,5,5,,103194429,3157,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
271,625237,4,7,,103194429,3157,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
272,625238,4,7,,103194429,3157,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
273,625239,4,7,,103194429,3157,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
274,625240,1,9,,103194429,3157,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
275,625241,4,7,,103194429,3157,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
276,625242,4,7,,103194429,3157,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
277,625243,5,5,,103194429,3157,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
278,625244,5,5,,103194429,3157,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
279,625245,5,5,,103194429,3157,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
280,625246,1,9,,103194429,3157,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
281,625247,5,5,,103194429,3157,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
282,625248,5,5,,103194429,3157,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
283,625249,5,5,,103194429,3157,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
284,625250,5,5,,103194429,3157,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
285,625251,5,5,,103194429,3157,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
286,625252,4,7,,103194429,3157,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
287,625253,4,7,,103194429,3157,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
288,625254,4,7,,103194429,3157,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
289,625255,4,7,,103194429,3157,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
290,625256,4,7,,103194429,3157,Active,266667.0,6531.0,0.188,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
291,625257,4,7,,103194429,3157,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
292,625258,4,7,,103194429,3157,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
293,625259,4,7,,103194429,3157,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
294,625260,3,4,,103194429,3157,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
295,625261,3,4,,103194429,3157,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
296,625262,3,4,,103194429,3157,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
297,625263,4,7,,103194429,3157,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
298,625264,3,4,,103194429,3157,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
299,625265,1,6,,103194429,3157,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
300,625266,3,4,,103194429,3157,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
301,625267,3,4,,103194429,3157,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
302,625268,4,2,,103194429,3157,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
303,625268,4,2,,103194429,3157,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
304,625268,4,2,,103194429,3157,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
305,625268,4,2,,103194429,3157,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
306,625269,4,7,,103194429,3157,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
307,625270,4,7,,103194429,3157,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
308,625271,5,5,,103194429,3157,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
309,625272,3,4,,103194429,3157,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
310,625273,4,6,,103194429,3157,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
311,625274,1,6,,103194429,3157,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
312,625275,3,4,,103194429,3157,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
313,625279,1,3,,103194429,3157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
314,625280,1,3,,103194429,3157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
315,625281,1,3,,103194429,3157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
316,625282,1,3,,103194429,3157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
317,625283,1,3,,103194429,3157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
318,625284,1,3,,103194429,3157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
319,625285,1,3,,103194429,3157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
320,625286,1,3,,103194429,3157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
321,625287,1,3,,103194429,3157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
322,625288,1,3,,103194429,3157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
323,625289,1,3,,103194429,3157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
324,625290,1,3,,103194429,3157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
325,625291,1,3,,103194429,3157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
326,625292,1,3,,103194429,3157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
327,651635,1,3,,90341261,3157,Inconclusive,171543895.0,6311.0,14.1254,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
328,651828,1,2,,92309056,3157,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
329,651828,1,2,,121362602,3157,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
330,651965,1,1,,124883384,3157,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
331,652106,1,1,,90341261,3157,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
332,652106,1,1,,124883384,3157,Inconclusive,586067.0,6622.0,5.6234,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
333,679585,1,8,,103194429,3157,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 0.1 uM, Doxazosin: 50 uM) in MDR1-expressing LLC-PK1 cells",Other,11895100.0,
334,686970,1,2,,124883384,3157,Inconclusive,49168486.0,3417.0,25.1189,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
335,686971,1,2,,124883384,3157,Inconclusive,,,25.1189,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
336,686977,2,1,,49698667,3157,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
337,686978,1,1,,124883384,3157,Inconclusive,79154014.0,55775.0,12.5893,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
338,686979,1,1,,124883384,3157,Inconclusive,79154014.0,55775.0,28.1838,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
339,699539,1,7,,103194429,3157,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
340,699540,1,7,,103194429,3157,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
341,699541,1,7,,103194429,3157,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
342,720538,1,2,,90341261,3157,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
343,720554,1,3,,121362602,3157,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
344,720559,1,2,,90341261,3157,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
345,720572,1,2,,90341261,3157,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
346,720573,1,2,,90341261,3157,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
347,720579,2,1,,124883384,3157,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
348,720580,1,1,,124883384,3157,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
349,720641,1,2,,92241035,3157,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
350,720641,1,2,,92309056,3157,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
351,720717,1,3,,92309056,3157,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
352,723774,1,3,,103194429,3157,Active,,,49.0,TGI,Cytotoxicity against human PC3 cells assessed as concentration required for tumor growth inhibition after 48 hrs by sulforhodamine B assay,Confirmatory,23252794.0,
353,723780,1,3,,103194429,3157,Unspecified,,,,GI50,Cytotoxicity against human PC3 cells after 48 hrs by sulforhodamine B assay,Confirmatory,23252794.0,
354,743205,1,1,,90341261,3157,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
355,743205,1,1,,90341261,3157,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
356,743206,1,1,,90341261,3157,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
357,743206,1,1,,90341261,3157,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
358,743207,1,1,,90341261,3157,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
359,743207,1,1,,90341261,3157,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
360,743244,1,1,,90341261,3157,Inconclusive,,,6.3096,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
361,743268,1,1,,172080808,3157,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
362,743270,1,1,,172080808,3157,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
363,743271,1,1,,172080808,3157,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
364,743272,1,1,,172080808,3157,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
365,743344,1,1,,174007482,3157,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
366,743345,1,1,,174007482,3157,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
367,743346,1,1,,174007482,3157,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
368,743347,1,1,,174007482,3157,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
369,934043,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020211,Other,,
370,934044,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020211,Other,,
371,934045,1,3,,103194429,3157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020211",Other,,
372,934046,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020211,Other,,
373,934047,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020211,Other,,
374,934048,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020211,Other,,
375,934049,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020211,Other,,
376,934050,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020211,Other,,
377,934051,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020211,Other,,
378,934052,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020211,Other,,
379,934053,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020211,Other,,
380,934054,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020211,Other,,
381,934055,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020211,Other,,
382,934056,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020211,Other,,
383,934057,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020211,Other,,
384,934058,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020211,Other,,
385,934059,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020211,Other,,
386,934060,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020211,Other,,
387,934061,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020211,Other,,
388,973091,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020211,Other,,
389,973092,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020211,Other,,
390,973093,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020211,Other,,
391,973094,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020211,Other,,
392,973095,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020211,Other,,
393,973096,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020211,Other,,
394,973097,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020211,Other,,
395,973098,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020211,Other,,
396,973099,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020211,Other,,
397,973100,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020211,Other,,
398,973101,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020211,Other,,
399,973102,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020211,Other,,
400,973734,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020211,Other,,
401,973735,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020211,Other,,
402,973736,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020211,Other,,
403,973737,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020211,Other,,
404,973738,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020211,Other,,
405,973739,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020211,Other,,
406,973740,1,3,,103194429,3157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % water; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020211,Other,,
407,1053175,2,1,,178126816,3157,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
408,1053188,2,1,,164150159,3157,Inactive,,,,,Primary Screen Inhibitors of CD40 Signaling in BL2 Cells Measured in Cell-Based System Using Plate Reader - 7124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
409,1053260,1,4,,103194429,3157,Unspecified,118206.0,1813.0,,,Antagonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin assessed as inhibition of agonist-induced effect at 50 uM after 15 mins by luminometric analysis relative to haloperidol,Other,24088053.0,
410,1053262,1,4,,103194429,3157,Unspecified,118206.0,1813.0,,,Agonist activity at human recombinant dopamine D2 long receptor expressed in CHOK1 cells coexpressing mitochondrial apoaequorin at 100 uM by luminometric analysis relative to quinpirol,Other,24088053.0,
411,1053264,1,4,,103194429,3157,Unspecified,118228.0,1812.0,,,Antagonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as inhibition of agonist-induced cAMP accumulation at 100 uM preincubated for 10 mins prior to agonist addition measured after 30 mins by HTRF assay relative to SCH23390,Other,24088053.0,
412,1053266,1,4,,103194429,3157,Unspecified,118228.0,1812.0,,,Agonist activity at human recombinant dopamine D1 receptor expressed in CHOK1 cells assessed as stimulation of cAMP accumulation at 100 uM after 30 mins by HTRF assay relative to SKF81297,Other,24088053.0,
413,1079931,1,1,,103194429,3157,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
414,1079932,1,1,,103194429,3157,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
415,1079933,1,1,,103194429,3157,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
416,1079934,1,1,,103194429,3157,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
417,1079935,1,1,,103194429,3157,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
418,1079936,1,1,,103194429,3157,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
419,1079937,1,1,,103194429,3157,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
420,1079938,1,1,,103194429,3157,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
421,1079939,1,1,,103194429,3157,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
422,1079940,1,1,,103194429,3157,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
423,1079941,1,1,,103194429,3157,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
424,1079942,1,1,,103194429,3157,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
425,1079943,1,1,,103194429,3157,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
426,1079944,1,1,,103194429,3157,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
427,1079945,1,1,,103194429,3157,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
428,1079946,1,1,,103194429,3157,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
429,1079947,1,1,,103194429,3157,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
430,1079948,1,1,,103194429,3157,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
431,1079949,1,1,,103194429,3157,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
432,1097336,1,3,,103194429,3157,Unspecified,,,,,Drug level in Homo sapiens (human) whole blood assessed as retention time by UPLC-TOF-MS analysis,Other,,
433,1159580,2,1,,268735212,3157,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
434,1159580,2,1,,273002805,3157,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
435,1159583,2,1,,178126816,3157,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
436,1159607,2,1,,312309881,3157,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
437,1202267,1,1,,103194429,3157,Unspecified,,,50.0,IC50,Cytotoxicity against human PC3 cells after 48 hrs by WST-8 assay,Confirmatory,25874333.0,
438,1202268,1,2,,103194429,3157,Active,,,37.67,IC50,Cytotoxicity against human DU145 cells after 48 hrs by WST-8 assay,Confirmatory,25874333.0,
439,1202269,1,1,,103194429,3157,Active,,,27.89,IC50,Cytotoxicity against human LNCAP cells after 48 hrs by WST-8 assay,Confirmatory,25874333.0,
440,1224824,1,1,,174007482,3157,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
441,1224825,1,1,,174007482,3157,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
442,1224857,2,1,,174007482,3157,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
443,1224859,2,1,,90341261,3157,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
444,1224859,2,1,,174007482,3157,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
445,1224863,1,1,,176484340,3157,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
446,1224863,1,1,,176484904,3157,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
447,1224863,1,1,,316919499,3157,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
448,1224905,2,1,,92241035,3157,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
449,1224905,2,1,,92241035,3157,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
450,1224905,2,1,,92309056,3157,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
451,1224905,2,1,,92309056,3157,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
452,1229078,1,1,,103194429,3157,Active,,,19.0,IC50,Cytotoxicity against HEK293A cells transfected with alpha-1A adrenergic receptor assessed as cell viability by sulforhodamine B assay,Confirmatory,26005522.0,
453,1229079,1,1,,103194429,3157,Active,,,22.0,IC50,Cytotoxicity against HEK293A cells transfected with alpha-1D adrenergic receptor assessed as cell viability by sulforhodamine B assay,Confirmatory,26005522.0,
454,1259252,1,1,,174007482,3157,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
455,1259253,1,1,,174007482,3157,Active,169655958.0,,16.6261,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
456,1259255,1,1,,174007482,3157,Inconclusive,169655958.0,,23.485,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
457,1259256,1,1,,174007482,3157,Inconclusive,169655958.0,,23.485,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
458,1259309,1,1,,178126816,3157,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
459,1259310,1,1,,104170183,3157,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
460,1259311,1,1,,178126816,3157,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
461,1259325,1,2,,336956312,3157,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
462,1259370,2,2,,124671348,3157,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
463,1259370,2,2,,124671348,3157,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
464,1259370,2,2,,124671348,3157,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
465,1259389,1,1,,124671348,3157,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
466,1259406,1,1,,363920462,3157,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
467,1259406,1,1,1.0,363920462,3157,Active,26638650.0,3778.0,-0.351366,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
468,1259406,1,1,2.0,363920462,3157,Active,4758626.0,3779.0,-0.143428,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
469,1259406,1,1,3.0,363920462,3157,Active,5031823.0,10242.0,-0.269449,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
470,1259406,1,1,4.0,363920462,3157,Active,26051275.0,27345.0,-0.23489000000000002,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
471,1259406,1,1,5.0,363920462,3157,Inactive,160410009.0,389816.0,-0.00742263,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
472,1259406,1,1,6.0,363920462,3157,Inactive,26638650.0,3778.0,-0.0618066,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
473,1259406,1,1,7.0,363920462,3157,Inactive,4758626.0,3779.0,0.0698086,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
474,1259406,1,1,8.0,363920462,3157,Inactive,5031823.0,10242.0,-0.0306414,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
475,1259406,1,1,9.0,363920462,3157,Inactive,26051275.0,27345.0,-0.07286480000000001,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
476,1259406,1,1,10.0,363920462,3157,Inactive,5031823.0,10242.0,0.00735938,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
477,1259413,1,2,,104170183,3157,Inactive,47605623.0,173990.0,,,Modulators of fzo-1,Other,,
478,1259416,1,2,,164150159,3157,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
479,1259416,1,2,,340079849,3157,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
480,1259421,1,1,,164150159,3157,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
481,1259421,1,1,,340079849,3157,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
482,1259423,1,2,,354767955,3157,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
483,1259423,1,2,,354849315,3157,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
484,1259423,1,2,,354917343,3157,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
485,1259423,1,2,,355020518,3157,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
